Tom Loewald, Cambrex CEO

Af­ter Chi­nese CD­MO fails, Cam­brex ac­quires in­gre­di­ent man­u­fac­tur­er Snap­drag­on Chem­istry

While CD­MO Cam­brex has been ex­pand­ing steadi­ly through­out the year, its lat­est ac­qui­si­tion sees a deep­er dive in­to the ac­tive phar­ma­ceu­ti­cal in­gre­di­ent game.

The New Jer­sey-based CD­MO has agreed to ac­quire Snap­drag­on Chem­istry, a pro­duc­er of chem­i­cal ser­vices and API man­u­fac­tur­ing for bio­phar­ma cus­tomers. The deal will see Cam­brex ac­quire Snap­drag­on’s two fa­cil­i­ties in Waltham, MA. Cam­brex did not dis­close the deal amount to End­points News.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters